Review
Medicine, General & Internal
Jorge Cortes, Carolina Pavlovsky, Susanne Saussele
Summary: Tyrosine-kinase inhibitors have significantly altered the natural course of chronic myeloid leukaemia, allowing some patients to approach a near-normal life expectancy. Successful treatment requires understanding the patient's treatment goals, monitoring optimal response hallmarks, timely interventions, recognition of adverse events, and management of comorbidities.
Review
Biochemistry & Molecular Biology
Selvaraj Vimalraj
Summary: Angiogenesis is the formation of new blood vessels from existing ones. Abnormal angiogenesis, seen in tumor microenvironments, is characterized by distorted and leaky blood vessels with various shapes and high perfusion efficiency. Tumor angiogenesis plays a crucial role in cancer growth, invasion, and metastasis, and is tightly regulated by signaling networks. Targeting multiple signaling pathways involved in angiogenesis is important for effective antiangiogenic therapy. New therapeutic approaches, such as blocking specific proteins or genes, are being explored to dissect alternative angiogenesis mechanisms in tumor microenvironments.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2022)
Review
Hematology
Naranie Shanmuganathan, Timothy P. Hughes
Summary: The recent approval of asciminib as a treatment option for CML patients provides clinicians with more choices for therapy. Asciminib is a highly potent BCR-ABL1 inhibitor with limited off-target effects, but its position among other available TKIs is still unclear. There are many unanswered questions about the optimal use of asciminib.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Medicine, General & Internal
Courtney D. Dinardo, Harry P. Erba, Sylvie D. Freeman, Andrew H. Wei
Summary: Progress in acute myeloid leukaemia treatment has seen significant improvements in scientific understanding, prognostication tools, risk assessments, and incorporation of measurable residual disease into risk assessments. Recent updates in classification and recommendations by organizations such as WHO, ICC, and European LeukemiaNet have provided enhanced guidance for prognostic stratification and treatment response assessment. There have also been advancements in treatment options, leading to improved outcomes for both newly diagnosed and relapsed patients.
Article
Oncology
Michael Lauseker, Ruediger Hehlmann, Andreas Hochhaus, Susanne Saussele
Summary: The therapy after failing response milestones in CML is controversial, and there is a lack of information on the long-term survival of these patients. A study on patients from CML-study IV showed that the survival rate of patients who failed the failure milestones was approximately 10% lower than those who reached the milestones, suggesting a need for revising these milestones.
Article
Biochemistry & Molecular Biology
Marta Romo-Gonzalez, Carla Ijurko, Maria Teresa Alonso, Marta Gomez de Cedron, Ana Ramirez de Molina, Maria Eugenia Soriano, Angel Hernandez-Hernandez
Summary: Cancer cells exhibit an altered metabolism and increased production of ROS, both of which play important roles in cancer and have potential therapeutic implications. Recent studies have highlighted the importance of NOX enzymes in connecting ROS production and metabolic control. In this study, the relevance of NOX2 and NOX4 in regulating metabolism and mitochondrial function in CML cells was explored. The results support the role of NOX2 in controlling metabolism-related signaling pathways downstream of BCR-ABL, and highlight the role of NOX4 in altering mitochondrial function.
FREE RADICAL BIOLOGY AND MEDICINE
(2023)
Article
Oncology
Benjamin Lebecque, Celine Bourgne, Chinmay Munje, Juliette Berger, Thomas Tassin, Pascale Cony-Makhoul, Agnes Guerci-Bresler, Hyacinthe Johnson-Ansah, Wei Liu, Sandrine Saugues, Andrei Tchirkov, David Vetrie, Mhairi Copland, Marc G. Berger
Summary: The study found that the alteration of spliceosome in chronic myeloid leukemia (CML) cells is associated with the development of the disease and exhibits intraclonal heterogeneity. Additionally, the combination of spliceosome-targeted drug and TKI can effectively treat CML without affecting healthy cells.
Review
Hematology
Jerald Radich
Summary: Most cancer cases occur in low resource areas, where diagnosis and treatment can be especially challenging. Unique partnerships between non-profit organizations and pharmaceutical companies provide free drugs to CML patients worldwide, but performing molecular diagnostics in areas with unreliable electricity remains a major obstacle.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Chemistry, Medicinal
Donghwa Kim, Sang Won Choi, Jihee Cho, Jae-Hui Been, Kyoungsun Choi, Wenzhe Jiang, Jaeho Han, Jedo Oh, Changmin Park, Soongyu Choi, Songyi Seo, Koung Li Kim, Wonhee Suh, Sang Kook Lee, Sanghee Kim
Summary: Diabetic retinopathy is a leading cause of blindness associated with excessive angiogenesis. Researchers have developed a novel antiangiogenesis agent by modifying the structure of wondonin marine natural products, resulting in improved bioactivity and selectivity. This compound, 31, shows potential as a lead for developing small-molecule drugs to treat diabetic retinopathy and to uncover new mechanisms of angiogenesis.
JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Oncology
Qian Jiang, Richard A. Larson, Robert Peter Gale
Summary: The influence of economic considerations on therapy decisions for chronic myeloid leukaemia (CML) patients is significant, but the appropriateness and impact of this influence are still under consideration. In some cases, making treatment choices based on cost and availability may be the best approach. However, because TKI therapy significantly prolongs survival and can even cure some patients, ensuring access to TKI therapy for all individuals with CML is crucial.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Oncology
Michele Baccarani, Francesca Bonifazi, Simona Soverini, Fausto Castagnetti, Gabriele Gugliotta, Wael Saber, Noel Estrada-Merly, Gianantonio Rosti, Robert Peter Gale
Summary: This commentary discusses important questions regarding the treatment of chronic myeloid leukaemia (CML) and compares the benefits and risks of tyrosine kinase-inhibitor (TKI) therapy and transplantation. The authors suggest that a small proportion of patients with CML can achieve sustained therapy-free remission with TKI therapy, while others may need lifelong treatment. Transplants offer higher rates of leukaemia-free survival, but are associated with adverse events and complications. The authors propose that transplantation should be considered more often as a treatment option for CML patients unlikely to achieve therapy-free remission with TKI therapy.
Article
Oncology
Xiaojiao Zheng, Shixuan Hua, Hang Zhao, Zhou Gao, Dong Cen
Summary: Resistance to apoptosis induced by chemotherapy remains a challenge in the treatment of chronic myeloid leukemia (CML). This study found that overexpression of hepatocyte growth factor (HGF) reduced cell apoptosis induced by VP-16 (etoposide) in CML cells. The mechanism involved an increase in Bcl-2 protein expression level, inhibition of caspase-3/9 activation, and activation of the PI3K/Akt signaling pathway. Targeting HGF could be a potential strategy to overcome VP-16 resistance in CML.
Article
Medicine, General & Internal
Guido Bocci, Paola Orlandi, Maria Laura Manca, Chiara Rossi, Antonio Salvati, Maurizia Rossana Brunetto, Anna Solini
Summary: This study found that circulating biomarker profiles can predict the severity of chronic liver disease of NAFLD/NASH or HCV origin. In HCV patients, there was an inverse correlation between disease stage and circulating levels of BMP-9 and VEGF-A, while in NASH/NAFLD, direct correlations between stage and BMP-9 and VEGF-A circulating levels were observed.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Oncology
Govinda Poudel, Molly G. Tolland, Timothy P. Hughes, Ilaria S. Pagani
Summary: This article reviews the lack of response or relapse of chronic myeloid leukemia (CML) patients to current drug treatments, as well as new treatment strategies. Combination treatment strategies targeting alternative survival pathways may increase the response rate in CML patients.
Review
Hematology
Mhairi Copland
Summary: Despite the success of BCR-ABL-specific tyrosine kinase inhibitors (TKIs) in the treatment of chronic phase chronic myeloid leukemia (CML), blast phase CML (BP-CML) remains a challenging clinical need due to its rarity and heterogeneity. Further research and clinical trials are required to improve patient outcomes.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Hematology
Aleksander Skotnicki, Toshko J. Lissitchkov, Vasily Mamonov, Evgeny Buevich, Kazimierz Kuliczkowski, Stefcho Goranov, Janusz Kloczko, Anna Klukowska, Svetlana Stankovic, Liana Gercheva, Tatiana Chernova, Andrzej Hellmann, Anna Dmoszynska, Krystyna Zawilska, Alex Veldman, Christine Joch, Wilfried Seifert
THROMBOSIS RESEARCH
(2016)
Article
Hematology
Richard Greil, Petra Obrtlikova, Lukas Smolej, Tomas Kozak, Michael Steurer, Johannes Andel, Sonja Burgstaller, Eva Mikuskova, Liana Gercheva, Thomas Nosslinger, Tomas Papajik, Miriam Ladicka, Michael Girschikofsky, Mikulas Hrubisko, Ulrich Jager, Michael Fridrik, Martin Pecherstorfer, Eva Kralikova, Cristina Burcoveanu, Emil Spasov, Andreas Petzer, Georgi Mihaylov, Julian Raynov, Horst Oexle, August Zabernigg, Emilia Flochova, Stanislav Palasthy, Olga Stehlikova, Michael Doubek, Petra Altenhofer, Lisa Pleyer, Thomas Melchardt, Anton Klingler, Jiri Mayer, Alexander Egle
LANCET HAEMATOLOGY
(2016)
Article
Hematology
Robert Z. Orlowski, Liana Gercheva, Cathy Williams, Heather Sutherland, Tadeusz Robak, Tamas Masszi, Vesselina Goranova-Marinova, Meletios A. Dimopoulos, James D. Cavenagh, Ivan Spicka, Angelo Maiolino, Alexander Suvorov, Joan Blade, Olga Samoylova, Thomas A. Puchalski, Manjula Reddy, Rajesh Bandekar, Helgi van de Velde, Hong Xie, Jean-Francois Rossi
AMERICAN JOURNAL OF HEMATOLOGY
(2015)
Article
Hematology
Wolfgang U. Knauf, Toshko Lissitchkov, Ali Aldaoud, Anna M. Liberati, Javier Loscertales, Raoul Herbrecht, Gunnar Juliusson, Gerhard Postner, Liana Gercheva, Stefan Goranov, Martin Becker, Hans-Joerg Fricke, Francoise Huguet, Ilaria Del Giudice, Peter Klein, Karlheinz Merkle, Marco Montillo
BRITISH JOURNAL OF HAEMATOLOGY
(2012)
Article
Hematology
Andreas L. Petzer, Dominic Fong, Thomas Lion, Irina Dyagil, Zvenyslava Masliak, Andrija Bogdanovic, Laimonas Griskevicius, Sandra Lejniece, Stefan Goranov, Liana Gercheva, Aleksandar Stojanovic, Dontcho Peytchev, Nikolay Tzvetkov, Rasa Griniute, Atanas Stanchev, Thomas Grubinger, Marthin Kwakkelstein, Peter Schuld, Guenther Gastl, Dominik Wolf
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
(2012)
Article
Hematology
T. Lissitchkov, M. Matysiak, K. Zavilska, P. Laguna, L. Gercheva, A. Antonov, N. Cabrera, J. A. Aznar, M. K. Woodward, A. Paez
Article
Hematology
T. Lissitchkov, M. Matysiak, K. Zavilska, P. Laguna, L. Gercheva, A. Antonov, A. Moret, P. Caunedo, J. A. Aznar, M. K. Woodward, A. Paez
Article
Hematology
M. J. Manco-Johnson, C. L. Kempton, M. T. Reding, T. Lissitchkov, S. Goranov, L. Gercheva, L. Rusen, M. Ghinea, V. Uscatescu, V. Rescia, W. Hong
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2013)
Article
Oncology
Thomas Elter, Liana Gercheva-Kyuchukova, Halyna Pylylpenko, Tadesuz Robak, Branimir Jaksic, Grigoriy Rekhtman, Slawomira Kyrcz-Krzemien, Mykola Vatutin, Jingyang Wu, Cynthia Sirard, Michael Hallek, Andreas Engert
Article
Medicine, General & Internal
Antonio Antonov, Liana Gercheva, Nadezhda Stefanova, Maria Tzaneva, Trifon Chervenkov
Article
Medicine, General & Internal
Ilina Micheva, Trifon Chervenkov, Canka Ruseva, Liana Gercheva
Article
Medicine, General & Internal
Liana Gercheva, Stela Dimitrova, Ilina Micheva
Article
Medicine, General & Internal
Ilina Micheva, Liana Gercheva, Panos Ziros, Nicholas Zoumbos
Article
Medicine, General & Internal
Liana Gercheva, Antonina Zhelyazkova, Mina Micheva, Neli Gurova, Maria Tzaneva, Georgi Balatzenko
Article
Medicine, General & Internal
Tsvetelina Kostadinova, Liliya Ivanova, Zhivka Stoykova, Tatina Todorova, Liana Gercheva, Dobromir Staykov, Denitsa Tsaneva